Your browser doesn't support javascript.
loading
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
Blauvelt, Andrew; Tsai, Tsen-Fang; Langley, Richard G; Miller, Megan; Shen, Yaung-Kaung; You, Yin; Yang, Ya-Wen; Papp, Kim A; Puig, Luis.
Afiliación
  • Blauvelt A; Oregon Medical Research Center, Portland, Oregon. Electronic address: ablauvelt@oregonmedicalresearch.com.
  • Tsai TF; National Taiwan University Hospital, Taipei, Taiwan.
  • Langley RG; Dalhousie University, Halifax, Nova Scotia, Canada.
  • Miller M; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Shen YK; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • You Y; Janssen Research & Development, LLC, Spring House, Pennsylvania.
  • Yang YW; Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania.
  • Papp KA; K Papp Clinical Research and Probity Research, Inc, Waterloo, Ontario, Canada.
  • Puig L; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
J Am Acad Dermatol ; 86(4): 827-834, 2022 04.
Article en En | MEDLINE | ID: mdl-34798201
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Neoplasias Cutáneas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Am Acad Dermatol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Neoplasias Cutáneas Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: J Am Acad Dermatol Año: 2022 Tipo del documento: Article